What kind of targeted drug is Platinib?

Platinib, trade name: GAVRETO (GAVRETO), is a new type of targeted therapy drug, mainly for cancer patients with RET gene fusion or mutation. As a highly selective RET inhibitor, Platinib effectively prevents the proliferation of cells expressing RET gene mutations by inhibiting the phosphorylation of RET and its downstream molecules, thereby achieving therapeutic purposes.

Platinib has shown excellent results in the treatment of non-small cell lung cancer (NSCLC) with mutations in the RET gene. Non-small cell lung cancer is a common type of lung cancer, accounting for approximately 85% of all lung cancer cases. RETThe proportion of fusion patients in non-small cell lung cancer is about 1%-2% , mainly occurring in non-smokers. Platinib can specifically inhibit the RET fusion gene and significantly improve the survival rate and quality of life of patients. Clinical trial results show that platinib has a significant effect on RETfusion-positive NSCLC patients. Both treatment-naïve and previously treated patients have shown a high objective response rate (ORR) and a good disease control rate.

In addition, platinib is approved for the treatment of RETmutated medullary thyroid cancer (MTC) and RETfusion-positive thyroid cancer. Medullary thyroid cancer is a rare type of thyroid cancer that is often associated with mutations in the RET gene. Platinib effectively controls the growth and spread of tumors by inhibiting RET gene mutations. Platinib has also shown significant therapeutic efficacy in patients with advanced or metastatic thyroid cancer who require systemic therapy and are refractory to radioactive iodine.

Platinib is an oral, once-daily drug that is highly potent and highly selective. It can effectively treat cancers caused by RET gene mutations without significantly affecting normal cells. However, as a drug, Platinib may also be associated with some side effects, such as musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, etc. When using platinib, patients should strictly follow the doctor's instructions, pay attention to usage and dosage, and conduct relevant examinations regularly to monitor the drug's effects and potential side effects.

Platinib is currently on the market in China, but it has not yet been included in medical insurance. The price is around tens of thousands of yuan. For specific results, please consult the local hospital pharmacy. The cheaper ones abroad are mainly the Laos version of the generic version of Platinib, which costs about more than 3,000 yuan and has basically the same ingredients as the domestic original drug.

In general, platinib, as an innovative targeted drug, brings new treatment hope and survival opportunities to patients with non-small cell lung cancer and thyroid cancer suffering from RET gene mutations. Through rational medication and scientific management, patients can achieve better therapeutic effects and quality of life.

xa0

Reference link:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ponatinib